A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies

Inclusion Criteria:

- Subject is male or female, aged at least 18 years.

- Subject has a histologically or cytologically confirmed diagnosis of an advanced,
malignant, incurable solid tumor(s) or lymphoma that is metastatic and/or
unresectable and/or for which standard curative measures either are not applicable,
or do not exist, or are no longer effective. Subjects with curative treatment options
are not eligible for the protocol.

- Subject is not receiving any active treatment for his/her malignancy (except for
prostate cancer subjects receiving luteinizing hormone-releasing hormone (LHRH)
agonists and antiandrogens such as: Flutamide, Dutasteride, and Finasteride).

- Subject's Eastern Cooperative Group (ECOG) performance status is 0, 1 or 2 at
Screening.

- Subject has acceptable liver function at Screening

- Subject has a normal serum creatinine.

- Subject has acceptable hematologic status at Screening

- Female subjects of childbearing potential (i.e., women who have not been surgically
sterilized or have not been post-menopausal for at least one year), and male subjects
with partners of childbearing potential, must agree to use medically acceptable
methods of contraception beginning on Study Day 1 and continuing until at least four
weeks after administration of the subject's final dose of RRx-001.

Exclusion Criteria:

- Impaired cardiac function that in the opinion of the Investigator could interfere
with the conduct of the study or could put the subject at unacceptable risk.

- Right-to-left, bidirectional, or transient right-to-left cardiac shunts.

- Subjects with a history of acute cerebral infarction or TIAs within 90 days prior to
Study Day 1.

- Acute myocardial infarction or acute coronary syndromes less than one year prior to
enrollment.

- Serious ventricular arrythmias or high risk for arrhythmias due to prolongation of
the QT interval.

- Subjects who experienced a major surgery, radiotherapy, or immunotherapy within the
last 21 days prior to Study Day 1 (limited palliative radiation is allowed within 14
days prior to Study Day 1).

- Chemotherapy regimens with delayed toxicity within the 28 days prior to Study Day 1
(except for nitrosourea or mitomycin C treatments within 42 days prior to Study Day
1).

- Chemotherapy regimens given continuously or on a weekly basis that Investigator
believes to have a limited potential for delayed toxicity within 14 days prior to
Study Day 1.

- Use of an investigational anti-cancer drug within 42 days prior to Study Day 1.

- Subject has symptomatic and/or untreated central nervous system metastases and/or
intracranial hypertension.

- Subject has a known history of an active and/or an uncontrolled infection with
hepatitis A or hepatitis B.

- Subject with a known history of a positive HIV status.

- Subjects with pulmonary edema.

- Subjects with respiratory failure

- Subjects with severe emphysema, pulmonary emboli, pulmonary fibrosis or other
conditions that cause pulmonary hypertension due to compromised pulmonary arterial
vasculature.

- Subjects with Raynaud's syndrome.

- Subjects with a serious co-morbid medical condition.

- If female, subject is pregnant and/or breastfeeding.

- Any subject with congenital or acquired methemoglobinemia.

- Any subject with a history of inherited anemia or hemoglobinopathy including but not
limited to hereditary spherosytosis, hereditary elliptocytosis, hereditary
ovalocytosis,